Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.

doi:10.1111/ejh.14294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.

European journal of haematology - 1 Dec 2024

Redondo Sara, García-Cadenas Irene, Esquirol Albert, Portos J M, Iranzo Eva, Arguello-Tomas Miguel, Saavedra Silvana, Oñate Guadalupe, Caballero Ana-Carolina, Garrido Ana, López Jordi, Muntañola Ana, Paviglianiti Annalisa, Miqueleiz Sara, Sierra Jorge, Briones Javier, Martino Rodrigo

Abstract excerpt

OBJECTIVE: This retrospective single center study aims to describe changes in the severity and organ-specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches. METHODS: Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA-matched or 1-allele mismatched related or unrelated donors. Fifty-eight (26%) received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcineurin Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Graft vs Host Disease

Share to Histocompatibility

Share to Methotrexate

Share to Mycophenolic Acid

Share to Sirolimus

Share to Transplantation Conditioning

Source

Open in PubMed

Identifiers

PMID: 39155459
DOI: 10.1111/ejh.14294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.PMID 39155459Read ↗

Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and TreatmentSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesSemantic proximity Read ↗

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.Semantic proximity Read ↗

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationSemantic proximity Read ↗

Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridgingSemantic proximity Read ↗

Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantationSemantic proximity Read ↗

Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Graft-versus-host diseaseSemantic proximity Read ↗

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantationSemantic proximity Read ↗

Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directionsSemantic proximity Read ↗

Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationSemantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.